ClinicalTrials.gov
ClinicalTrials.gov Menu

Rivaroxaban for Patients With Antiphospholipid Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02926170
Recruitment Status : Completed
First Posted : October 6, 2016
Last Update Posted : May 10, 2018
Sponsor:
Information provided by (Responsible Party):
Hospital Universitari Vall d'Hebron Research Institute

Brief Summary:
Long-term anticoagulation is widely used for secondary thromboprophylaxis in the antiphospholipid syndrome (APS) due to the high risk of recurrent events. Currently anticoagulation with vitamin K antagonists (VKAs) is the standard of care but have unpredictable pharmacodynamic properties that requiere monitoring for dose adjustment. Rivaroxaban, an orally active direct factor Xa inhibitor, has been shown to be effective and safe compared with warfarin for the treatment of venous thromboembolism and non valvular atrial fibrillation in major RCTs. No studies had been published in APS.The aim of the study is to investigate the efficacy and safety of rivaroxaban in preventing recurrent thrombosis in patients with APS compared with acenocoumarol

Condition or disease Intervention/treatment Phase
Antiphospholipid Syndrome Drug: Rivaroxaban Drug: acenocumarol Phase 3

Detailed Description:
This is a phase 3 randomized, multicenter, non-inferiority open-label RCT. 190 eligible APS patients with arterial or venous thrombotic history receiving acenocoumarol will be stratified according the presence of SLE and venous/arterial thrombotic history and randomized (1:1) either to continue vitamin K antagonists (standard of care, normalized ratio (INR) 2-3 or 2.5 to 3.5 in those with recurrent thrombotic episodes) or to switch to rivaroxaban (20 mg/day). The primary efficacy outcome is the development of any thrombotic event during the study period. Secondary efficacy outcomes include time to thrombosis, type of thrombosis (arterial or venous), overall causes of death, evaluation of a prognostic biomarker panel of recurrent thrombosis. The primary safety outcome will be major bleeding. Secondary safety outcomes include any adverse event and minor bleeding.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 190 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Rivaroxaban Versus Acenocumarol for Secondary Thromboprophylaxis in Patients With Antiphospholipid Syndrome: a Randomized, Prospective, Phase III Study. Analysis of Stratification Prognostic Factors
Actual Study Start Date : March 13, 2013
Actual Primary Completion Date : December 31, 2017
Actual Study Completion Date : December 31, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Rivaroxaban

Arm Intervention/treatment
Experimental: rivaroxaban
Rivaroxaban 20 mg per day
Drug: Rivaroxaban
Rivaroxaban will be started at 20 mg/day. Dose will be adjusted according to Cr Clearance. Cr Clearance 30-49 ml/min will receive 15 mg/day.
Other Name: XARELTO

Active Comparator: acenocumarol
INR adjusted dose
Drug: acenocumarol
Doses will be adjusted according to INR
Other Name: SINTROM




Primary Outcome Measures :
  1. Developement of a new thrombotic event (arterial or venous), confirmed by appropiate imaging studies [ Time Frame: 36 months ]
    Stroke or transient ischemic attack, myocardial infarction, peripheral arterial thrombosis, cerebral vein thrombosis, deep-vein thrombosis, or pulmonary embolism) that was confirmed by adjudication

  2. Incidence of major bleeding [ Time Frame: 36 months ]
    Major bleeding is defined as clinically overt bleeding associated with any of the following: fatal bleeding causing death, involvement of a critical anatomic site (intracranial, spinal, intraocular, pericardial, articular, retroperitoneal, or intramuscular with compartment syndrome) or need for surgery or angiographic intervention to stop haemorrhage, fall in haemoglobin concentration of at least 20 g/L in 24 hours, and/or requiring non-planned transfusion of ≥2 units of packed red blood cells or whole blood


Secondary Outcome Measures :
  1. Incidence of any treatment-Emergent Adverse events [ Time Frame: 36 months ]
    i) all adverse events; ii) serious adverse events (SAE); iii) all bleeding events; iv) overall causes of death

  2. Death due to thrombotic events [ Time Frame: 36 months ]
    Death as result of a thrombotic event

  3. Time to the first thrombotic event [ Time Frame: 36 months ]
    Time (months) from the treatment onset up to the thrombotic event

  4. Location of thrombotic events [ Time Frame: 36 months ]
    Location (arterial or venous) whenre the thrombotic event occurred

  5. Evaluation of a prognostic biomarker panel [ Time Frame: 36 months ]
    Measuremnt of D-dimer, P-selectine and Von-willebrand factor



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with thrombotic antiphsopholipd syndrome
  • Treated with acenocumarol for a minimum period of 6 months
  • Positivity for Lupus anticoagulant and/or anti-cardiolipin or anti-B2GPI antibodies IgG or IgM≥40

Exclusion Criteria:

  • Major haemorrhage (cerebral or gastrointestinal) within the previous 6 months
  • Neurosurgery within the previous 4 weeks
  • Any surgery within the previous 10 days
  • Active peptic ulcus
  • ALT or GPT >120 UI/mL non-lupus related in the previous 30 days
  • Platelets <30x10E9 in the previous 30 days
  • Recent diagnosed malignancy
  • Any criteria listed in the summary of the produt characterisitcs (SPC)
  • Renal disease with a creatinine clearance <30 mL/min or with a known uncontrolled renal disease
  • Concomitant administration of drugs that could interfere with CYP3A4

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02926170


Locations
Spain
Vall d'Hebron University Hospital
Barcelona, Spain, 08035
Sponsors and Collaborators
Hospital Universitari Vall d'Hebron Research Institute
Investigators
Principal Investigator: Josefina Cortes, MD,pHD Vall d'Hebron Research Institute

Responsible Party: Hospital Universitari Vall d'Hebron Research Institute
ClinicalTrials.gov Identifier: NCT02926170     History of Changes
Other Study ID Numbers: 2010-019764-36
First Posted: October 6, 2016    Key Record Dates
Last Update Posted: May 10, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Syndrome
Antiphospholipid Syndrome
Disease
Pathologic Processes
Autoimmune Diseases
Immune System Diseases
Rivaroxaban
Acenocoumarol
Factor Xa Inhibitors
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anticoagulants